AAAAAA

   
Results: 1-11 |
Results: 11
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys
Authors: Hart, TK Cook, RM Zia-Amirhosseini, P Minthorn, E Sellers, TS Maleeff, BE Eustis, S Schwartz, LW Tsui, P Appelbaum, ER Martin, EC Bugelski, PJ Herzyk, DJ
Citation: Tk. Hart et al., Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys, J ALLERG CL, 108(2), 2001, pp. 250-257
Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice
Authors: Hepburn, TW Hart, TK Horton, VL Sellers, TS Tobia, LP Urbanski, JJ Shi, W Davis, CB
Citation: Tw. Hepburn et al., Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice, J PHARM EXP, 298(3), 2001, pp. 886-893
Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice
Authors: Herzyk, DJ Gore, ER Polsky, R Nadwodny, KL Maier, CC Liu, S Hart, TK Harmsen, AG Bugelski, PJ
Citation: Dj. Herzyk et al., Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice, INFEC IMMUN, 69(2), 2001, pp. 1032-1043
In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone
Authors: Yue, TL Chen, J Bao, WK Narayanan, PK Bril, A Jiang, W Lysko, PG Gu, JL Boyce, R Zimmerman, DM Hart, TK Buckingham, RE Ohlstein, EH
Citation: Tl. Yue et al., In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone, CIRCULATION, 104(21), 2001, pp. 2588-2594
Nonlinear dynamics in the progression of atherosclerotic fatty streaks: Morphometric analysis
Authors: Bugelski, PJ Maleeff, BE Klinkner, AM Louden, CS Hart, TK
Citation: Pj. Bugelski et al., Nonlinear dynamics in the progression of atherosclerotic fatty streaks: Morphometric analysis, MICROS MICR, 6(6), 2000, pp. 532-541
Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?
Authors: Black, LE Green, JD Rener, J Dayan, A Cavagnaro, JA Spindler, P Bussiere, JL Bouchard, P Inoue, T Thomas, PT Essayan, DM Gillett, NA Hart, TK Hastings, K House, RV Latta, D Liminga, U Treacy, G Wierda, D
Citation: Le. Black et al., Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?, HUM EXP TOX, 19(4), 2000, pp. 205-206
Preclinical development of keliximab, a Primatized (TM) anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model andsafety studies
Authors: Bugelski, PJ Herzyk, DJ Rehm, S Harmsen, AG Gore, EV Williams, DM Maleeff, BE Badger, AM Truneh, A O'Brien, SR Macia, RA Wier, PJ Morgan, DG Hart, TK
Citation: Pj. Bugelski et al., Preclinical development of keliximab, a Primatized (TM) anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model andsafety studies, HUM EXP TOX, 19(4), 2000, pp. 230-243
Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4
Authors: Sharma, A Davis, CB Tobia, LAP Kwok, DC Tucci, MG Gore, ER Herzyk, DJ Hart, TK
Citation: A. Sharma et al., Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4, J PHARM EXP, 293(1), 2000, pp. 33-41
Flow cytometry in the preclinical development of biopharmaceuticals
Authors: Gossett, KA Narayanan, PK Williams, DM Gore, ER Herzyk, DJ Hart, TK Sellers, TS
Citation: Ka. Gossett et al., Flow cytometry in the preclinical development of biopharmaceuticals, TOX PATHOL, 27(1), 1999, pp. 32-37
Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonalantibody directed to human interleukin-5, in monkeys
Authors: Zia-Amirhosseini, P Minthorn, E Benincosa, LJ Hart, TK Hottenstein, CS Tobia, LAP Davis, CB
Citation: P. Zia-amirhosseini et al., Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonalantibody directed to human interleukin-5, in monkeys, J PHARM EXP, 291(3), 1999, pp. 1060-1067
TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells - Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease
Authors: Yue, TL Ni, J Romanic, AM Gu, JL Keller, P Wang, CL Kumar, S Yu, GL Hart, TK Wang, XK Xia, ZG DeWolf, WE Feuerstein, GZ
Citation: Tl. Yue et al., TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells - Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease, J BIOL CHEM, 274(3), 1999, pp. 1479-1486
Risultati: 1-11 |